RxDoctor Payments DataLook up a doctor →

William Larsen, MD

Family Medicine · Charlotte, NCNPI 1164483004

Payments from drug & device makers

$73,987in general payments, 2019–2025

Across 1,490 payments — averaging $49.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$53K
  • Viiv Healthcare Company$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$2K
  • AstraZeneca$2K
  • AbbVie$2K
  • plus $11K from 54 others

What the payments were for

  • Consulting fees$3,1404%
  • Speaking & faculty fees$40,44155%
  • Travel & lodging$5,0707%
  • Food & beverage$25,16534%
  • Education$1710%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead224$53,107
Viiv Healthcare Company112$2,261
Novo Nordisk172$2,171
Lilly USA, LLC101$1,841
AstraZeneca101$1,694
AbbVie(2 entities)93$1,509
Pfizer90$1,401
Sanofi-aventis U.S. LLC57$1,093
Merck70$1,053
Johnson & Johnson(2 entities)51$762
Bayer38$596
Amarin Pharma, Inc.34$523
Boehringer Ingelheim30$495
Amgen27$472
Takeda Pharmaceuticals U.S.A., Inc.19$390
Kowa Pharmaceuticals America, Inc.40$372
Sumitomo Pharma America, Inc.12$284
Biohaven Pharmaceuticals, Inc.17$267
Neos Therapeutics, LP15$250
Novartis14$225
Xeris Pharmaceuticals, Inc.12$222
Biohaven Pharmaceutical Holding Company Ltd.9$209
Phathom Pharmaceuticals, Inc.10$209
Exact Sciences10$207
Esperion Therapeutics, Inc.12$206
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC13$204
Eisai Inc.13$197
Idorsia Pharmaceuticals US Inc9$191
Theratechnologies Inc.7$158
GSK10$150
Tolmar, Inc.7$127
Hologic Sales And Service, LLC5$113
Astellas Pharma US Inc2$98
Axsome Therapeutics, Inc.5$94
Optinose US, Inc.4$67
Dexcom, Inc.3$63
Cranial Technologies, Inc4$60
Aytu Biopharma, Inc.4$59
Shield Therapeutics Inc3$53
Avanir Pharmaceuticals, Inc.3$46
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$43
Abbott2$40
Verity Pharmaceuticals Inc.1$33
Corcept Therapeutics2$32
E.r. Squibb & Sons, L.L.C.2$32
Paratek Pharmaceuticals, Inc.2$31
Philips North America LLC1$25
Antares Pharma, Inc.1$22
Clarus Therapeutics Inc.1$22
Upsher-smith Laboratories LLC1$19
Braintree Laboratories, Inc.1$18
Organon1$17
Medtronic1$17
Sebela Pharmaceuticals Inc.1$17
Jazz Pharmaceuticals Inc.1$16
Amneal Pharmaceuticals LLC1$15
Mylan Institutional Inc.1$14
IBSA Pharma Inc.1$14
Bausch Health US, LLC1$14
Teva Pharmaceuticals USA, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$73,987 in reported general payments places this provider in the 95th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$80,425
Medicare patients
335
Services billed
1,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala53$214,403
OdefseyEmtricitab/Rilpiviri/Tenof Ala56$203,135
GenvoyaElviteg/Cob/Emtri/Tenof Alafen36$157,357
JardianceEmpagliflozin108$137,799
OzempicSemaglutide110$130,445
EliquisApixaban143$124,617
Tresiba Flextouch U-200Insulin Degludec116$69,843
JanuviaSitagliptin Phosphate76$68,143
XareltoRivaroxaban51$59,193
TrulicityDulaglutide35$48,972
FarxigaDapagliflozin Propanediol46$47,343
DescovyEmtricitabine/Tenofov Alafenam19$41,256
TriumeqAbacavir/Dolutegravir/Lamivudi11$40,488
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog47$26,366
VascepaIcosapent Ethyl31$21,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$53,107$413,016108 claims
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$2,171$167,084138 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$495$158,337134 claims
PfizerEliquis$1,401$124,617143 claims
MerckJanuvia, Belsomra$1,053$74,38088 claims
Johnson & JohnsonXarelto$762$59,19351 claims
AstraZenecaFarxiga, Symbicort$1,694$54,77173 claims
Lilly USA, LLCTrulicity$1,841$48,97235 claims
GSKTrelegy Ellipta, Arexvy, Incruse Ellipta, Breo Ellipta$150$41,75983 claims
Viiv Healthcare CompanyTriumeq$2,261$40,48811 claims
Astellas Pharma US IncMyrbetriq$98$21,04031 claims
Sumitomo Pharma America, Inc.Gemtesa$284$10,23712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →